Profile
Sarah Ankri is currently the Director at France Biotech Association since 2014.
Prior to this, she worked as the Chief Financial Officer at Théraclion SA from 2013 to 2014 and as the Vice President-Finance at Lysogene SA. She also worked as a Manager-Financial Audit at Ernst & Young Audit SAS (France).
Ms. Ankri completed her undergraduate degree from Institut National Agronomique Paris-Grignon.
Sarah Ankri active positions
| Companies | Position | Start |
|---|---|---|
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates an organisation for growth of health industry | Director/Board Member | 12/06/2014 |
Former positions of Sarah Ankri
| Companies | Position | End |
|---|---|---|
Ernst & Young Audit SAS (France)
Ernst & Young Audit SAS (France) Miscellaneous Commercial ServicesCommercial Services Provides Auditing & Accounting Services | Comptroller/Controller/Auditor | - |
| LYSOGENE | Director of Finance/CFO | - |
| THERACLION | Director of Finance/CFO | - |
Training of Sarah Ankri
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Institut National Agronomique Paris-Grignon
Institut National Agronomique Paris-Grignon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ernst & Young Audit SAS (France)
Ernst & Young Audit SAS (France) Miscellaneous Commercial ServicesCommercial Services Provides Auditing & Accounting Services | Commercial Services |
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates an organisation for growth of health industry | Commercial Services |
Théraclion SA
Théraclion SA Medical SpecialtiesHealth Technology Manufactures and markets utlra sound medical products | Health Technology |
Lysogene SA
Lysogene SA BiotechnologyHealth Technology Engages in research and clinical development of gene therapy for neurodegenerative disorders | Health Technology |
- Stock Market
- Insiders
- Sarah Ankri
















